Phase 2 N=48 Double-Blind Treatment of Major Depressive Disorder With Vilazodone
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale (MADRS) — 13.9; 12.7; 14.5; 13.2 units on a scale — p=0.342
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=244 A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
Opioid-induced Constipation
Primary: Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week — 1.42; 1.98; 3.37; 3.64 spontaneous bowel movements…
Phase 2 N=68 Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Prostatic Neoplasm · Prostate Cancer · Prostatic Adenocarcinoma
Primary: Immune Response at Month 24 as Evaluated by IFN-γ ELISPOT Specific for PA2024 — 81.0; 61.1 IFN-γ ELISPOT (per 300,000 PBMC)
Phase 2 N=72 Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
Opioid Induced Bowel Dysfunction
Primary: Number of Participants With Adverse Events — 9; 6; 6; 5 participants
Phase 2 N=18 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Colon Mucinous Adenocarcinoma · Colon Signet Ring Cell Adenocarcinoma · Rectal Mucinous Adenocarcinoma
Primary: Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 0 Participants
Phase 2 N=199 LY353381 in Preventing Breast Cancer in Women With Hyperplasia
Breast Cancer
Primary: Change in Masood Score — -1.1; -0.8 units on a scale
Phase 2 N=71 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Treatment-related Mortality — 8.4 percentage of participants
Phase 2 N=12 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Incidence of Grade III-IV Acute GVHD — 25 percentage of participants
Phase 2 N=120 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
Dengue
Primary: Incidence of Any Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 — 0.0; 0.0; 0.0; 0.0 percentage of subjects
Phase 2 N=95 A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
Systemic Lupus Erythematosus
Primary: Number of Participants Successfully Able to Self-administer Their Observed First and Second Doses in Weeks 1 and 2 (Inside Clinic) — 89; 1 Participants
Phase 2 N=60 An Alternative Dosing Schedule of Varenicline for Smoking Cessation
Smoking Cessation
Primary: Change in Smoking Behavior — -6.3; -3.2 Change in Cigarettes Per Day
Phase 2 N=6 Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Pseudohypoparathyroidism Type 1a · Albright Hereditary Osteodystrophy
Primary: Change in Urine cAMP — 3048 fm/uL
Phase 2 N=20 Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions
Phase 2 N=50 AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Adhesive Capsulitis · Frozen Shoulder
Primary: Change From Baseline to Day 92 in Active Forward Flexion — 22.9; 37.5; 42.9; 23.8 degrees
Phase 2 N=322 Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
Adhesive Capsulitis · Frozen Shoulder
Primary: Change From Baseline to Day 95 in Active Forward Flexion — 41.0; 35.9 degrees